Chiu Bill, Sturgeon Cord, Angelos Peter
Department of Surgery, Division of Gastrointestinal & Endocrine Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Surgery. 2006 Sep;140(3):418-22. doi: 10.1016/j.surg.2006.03.021. Epub 2006 Jul 27.
We hypothesized that nonlocalizing sestamibi scans would correlate with multigland disease and persistent primary hyperparathyroidism.
We reviewed records for 401 consecutive patients who underwent parathyroidectomy from 1999 to 2004. Gender, age, preoperative imaging, surgical findings, gland weight and volume, and 6-month calcium levels (Ca) were examined.
We identified 289 women and 112 men, 297 of whom had a preoperative sestamibi scan localized to a single gland (localized group; LG). Ninety-six percent of the LG were found to have single-gland disease, and 4% had multigland disease (MGD). In the nonlocalized group (NLG), 76% had single-gland disease and 24% MGD. Mean gland weight was greater in the LG than in the NLG (1128 mg vs 699 mg; P < .05). Mean gland volume was larger in the LG (1.34 cc vs 0.89 cc; P < .05). A localizing sestamibi scan had a positive predictive value (PPV) of 96% and a likelihood ratio of 2.29 for predicting "curative" intraoperative parathyroid hormone drop after removal of a single abnormal gland. Patients were stratified into normocalcemic (NCa) and hypercalcemic (HCa) groups based on 6-month postoperative serum calcium data (n = 328). HCa incidence at 6 months did not differ significantly between the LG (5%) and NLG (3%). A localizing scan had a PPV of 95% for normocalcemia at 6 months. A nonlocalizing scan had a PPV of 21% for HCa at 6 months.
Nonlocalizing sestamibi scans were more common in primary hyperparathyroidism with MGD and were associated with smaller-volume abnormal glands found at operation. Preoperative sestamibi scan-results did not predict HCa at 6 months.
我们推测,未定位的 sestamibi 扫描结果与多腺体疾病及持续性原发性甲状旁腺功能亢进相关。
我们回顾了 1999 年至 2004 年期间连续接受甲状旁腺切除术的 401 例患者的记录。对性别、年龄、术前影像学检查、手术发现、腺体重量和体积以及术后 6 个月的血钙水平(Ca)进行了检查。
我们确定了 289 名女性和 112 名男性,其中 297 例术前 sestamibi 扫描显示为单个腺体定位(定位组;LG)。LG 中 96%被发现患有单腺体疾病,4%患有多腺体疾病(MGD)。在未定位组(NLG)中,76%患有单腺体疾病,24%患有 MGD。LG 的平均腺体重量大于 NLG(1128 mg 对 699 mg;P <.05)。LG 的平均腺体体积更大(1.34 cc 对 0.89 cc;P <.05)。定位性 sestamibi 扫描对于预测切除单个异常腺体后术中甲状旁腺激素“治愈性”下降的阳性预测值(PPV)为 96%,似然比为 2.29。根据术后 6 个月的血清钙数据(n = 328),将患者分为血钙正常(NCa)组和高钙血症(HCa)组。LG(5%)和 NLG(3%)术后 6 个月的 HCa 发生率无显著差异。定位扫描对于术后 6 个月血钙正常的 PPV 为 95%。未定位扫描对于术后 6 个月 HCa 的 PPV 为 21%。
未定位的 sestamibi 扫描在伴有 MGD 的原发性甲状旁腺功能亢进中更为常见,并且与手术中发现的体积较小的异常腺体相关。术前 sestamibi 扫描结果不能预测术后 6 个月的 HCa。